Video

Dr Melinda Magyari Explores What Registries Reveal About Pediatric MS

Melinda Magyari, MD, PhD, consultant neurologist, the Danish Multiple Sclerosis Center, Copenhagen University Hospital, explores what data registry have shown about factors that are linked with secondary progression in pediatric multiple sclerosis (MS).

Melinda Magyari, MD, PhD, Consultant neurologist, the Danish Multiple Sclerosis Center, Copenhagen University Hospital, explores what data registry have shown about factors that are linked with secondary progression in pediatric multiple sclerosis (MS).

Transcript

Have registry data revealed any factors related to secondary progression in pediatric MS?

The definition of secondary progression, it's very difficult. So you need to use a composite definition as a proxy. And that's a really hot topic, how to do that composite definition. Also because clinicians are reluctant to define the disease progression because there is no current treatment for secondary progressive MS. However, you see in 2 big, good registries that children progress slowly, but they reach secondary progression phase at a younger age, so 10 years younger than adults.

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Videos
Surbhi Sidana, MD, MBBS, Stanford University
Gordon Crofoot, MD, PA
David Awad, PharmD, BCOP
Merrill H. Stewart, MD
Saad Z. Usmani, MD, MBA, FACP, FASCO, Memorial Sloan Kettering Cancer Center
Andrew Evens, DO, MBA, MSc, deputy director for clinical services and chief physician officer, Rutgers Cancer Institute and Jack & Sheryl Morris Cancer Center
Hamlet Gasoyan, PhD
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo